How can we remove barriers to HIV testing outside of a GUM setting?
Approximately 32% of patients infected by HIV in the UK remain undiagnosed. 1 Delayed HIV diagnosis is responsible for HIV presentation at lower CD4 T-cell count and such patients respond less well to antiretroviral therapy. 2 At least 35% of HIVrelated deaths in 2005/6 in the UK were attributed to late diagnosis of infection. 3 Furthermore, delays in HIV diagnosis and initiation of antiretroviral therapy contribute to horizontal and vertical transmission of HIV infection. 4, 5 A recent study examined the factors which were significantly associated with GUM clinic patients (not exclusively attending for HIV testing) agreeing to GP contact. These factors included heterosexual orientation, initial GP referral, and not considering HIV testing to have negative implications for future mortgage and life insurance applications. 6 Two factors have been reported to us that impair the ability of non-genitourinary practitioners, both in primary care and other specialist care settings, to perform HIV testing. The first is pre-test counselling. We would argue that, as in other disease areas, the pre-test counselling is no longer necessary as there are clear health benefits in knowing about an HIV diagnosis which outweigh perceived disadvantages. This is consistent with a general move towards 'opt out' HIV testing in GUM clinics and antenatal services. 7 In rare, high risk, or acutely unwell cases, pre-test counselling may be the preferred option, but for the majority of patients it is not required. The second barrier cited is that of transparency about HIV testing for insurance company medical reports. However, the GP and insurance applicants are not required to notify insurers when negative tests are performed. 8 The life expectancy of a 25-year-old HIV-positive person, who is hepatitis C negative, has been estimated to be greater than 35 years 9 and this will increase as newer anti-retroviral drugs become available. Like other chronic and manageable conditions, an early diagnosis is essential to maximise individual and community health but this can only be achieved by the removal of barriers to widespread HIV testing across all hospital departments and primary care. We urge that the earlier diagnosis of HIV infection is made a clear priority and that the role of specialist genitourinary clinicians to enable better training, clear referral pathways, and the destigmatisation of testing in all care settings are key parts of the development of local sexual health networks. One participant, a female aged 44 years, who had detoxed off high prescribed doses of benzodiazepines 3 months previously, experienced an acute psychotic reaction within 1 hour of commencing norfloxacin and attempted suicide. Her condition quickly deteriorated and she developed repeated seizures; this progressed to status epilepticus, which failed to respond to treatment in ICU. Worryingly, her medical attendants continued to prescribe norfloxacin while in ICU. Her seizures were only controlled after finishing her norfloxacin course.
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Chronic use of benzodiazepines causes compensatory adaptions which cause GABA receptors to become less sensitive to GABA. On discontinuation of benzodiazepines, withdrawal symptoms typically develop which may persist for weeks or months. 1 Antagonism of the GABA A receptor is believed to be responsible for the CNS toxicity of fluoroquinolones affecting 1-4% of patients treated. 2 Fluoroquinolones have also been found to inhibit benzodiazepine receptor binding. 3 The results of this small study seem to confirm that adverse reactions to fluoroquinolones occur more frequently in the benzodiazepinedependent population than the 1-4% seen in the general public and may be severe.
Possible explanations for the adverse fluoroquinolone-induced reactions in the current reported patient group include:
• Fluoroquinolones compete directly with benzodiazepines for the benzodiazepine receptor site displacing benzodiazepines and precipitating an acute withdrawal effect. • Alterations in the GABA Abenzodiazepine receptor complex (during benzodiazepine tolerance/dependency status) may increase fluoroquinolone-induced stimulation of the receptor complex.
• Benzodiazepine dose-tapering and/or cessation might be associated with GABAergic underactivity but rebound neuro-excitation following fluoroquinolone exposure.
Participants were asked in the questionnaire about medication and alcohol or drug usage at time of adverse reaction. None of the participants reported anything which could explain their adverse reaction apart from the introduction of a fluoroquinolone. Physicians should, wherever possible, avoid fluoroquinolones in patients who are dependent on or withdrawing from chronic benzodiazepines. In Figure 1 (Effect of temperature and phlebotomy on the incidence of hyperkalaemia) the labels for the key were transposed. We apologise for this error. The corrected version is available online.
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